Latest News and Press Releases

WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Arcutis today announced the closing of its previously announced underwritten public offering.

Arcutis today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting.

WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today announced the pricing of its underwritten public offering of common stock.

Arcutis today announced the commencement of an underwritten public offering of $150.0 million of shares of its common stock

Arcutis and Sato today announced that the companies have entered into a strategic collaboration and licensing agreement for topical roflumilast in Japan.

Arcutis today reported financial results for the quarter and year ended December 31, 2023, and provided a business update.

Arcutis today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.

WESTLAKE VILLAGE, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...